EGFR and non-small cell lung carcinoma: Here, we confirmed that osimertinib is both efficacious and safe, which is beneficial for routine medical practice and therapeutic options for patients with T790M mutation-positive advanced NSCLC with EGFR-TKI resistance and poor PS, particularly for T790M-positive patients with no other treatment options.